Madrigal is a biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy, Rezdiffra (resmetirom), was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis.
Position Summary:
We are seeking a highly skilled Associate Director, Treasury to oversee and optimize our treasury operations, including banking, cash management, investments, intercompany transactions, foreign exchange (FX), and risk management. The Associate Director, Treasury will play a critical role in managing Madrigal’s global treasury functions, ensuring strong financial controls, liquidity management, and efficient cash forecasting. The successful candidate will bring extensive experience in corporate treasury operations, financial risk management, and process improvement to support the company’s growth and operational excellence.
Key Responsibilities:
- Oversee and manage global day-to-day treasury operations, including banking relationships, cash positioning, cash flow forecasting, and liquidity planning.
- Manage all operational banking activities, including account structures, payments, and collections.
- Evaluate and implement enhancements to cash and investment strategies to optimize returns while ensuring liquidity needs are met.
- Lead intercompany cash management, including funding strategies, netting, and settlements across subsidiaries.
- Monitor and manage foreign exchange (FX) exposure, develop hedging strategies, and execute FX transactions as needed.
- Enhance and maintain strong relationships with financial institutions and banking partners.
- Ensure compliance with internal treasury policies, external regulatory requirements, and industry best practices.
- Collaborate cross-functionally on risk management initiatives and work closely on insurance policy management and compliance.
- Drive process improvements and automation initiatives to enhance treasury efficiency and scalability.
- Support corporate financing activities, including debt management and compliance.
Qualifications & Experience:
- Bachelor’s degree in Finance, Accounting, Economics, or a related field (MBA, CPA, CTP or CFA preferred).
- 8+ years of progressive treasury experience in a corporate environment. Biotech, pharmaceutical, or life sciences industry strongly preferred.
- Strong expertise in banking operations, cash management, investment strategies, and FX risk management.
- Experience managing global organizations including intercompany transactions and global capital management operations; experience with global expansion a plus.
- Ability to work in a fast-paced dynamic environment and manage multiple priorities, while filling gaps as needed.
- Demonstrated ability to combine attention to detail with big picture perspective, operationalizing via excellence in project management and effectively managing multiple projects/priorities
- Excellent analytical, problem-solving, and communication skills.
- Strong leadership and stakeholder management capabilities.
#LI-Hybrid
Compensation: Base salary is determined by several factors that include, but are not limited to, a successful candidate's qualifications, skills, education, experience, business needs, and market demands. The role may also be eligible for bonus, equity, and comprehensive benefits, which include flexible paid time off (PTO), medical, dental, vision, and life and disability insurance.
Madrigal is an Equal Opportunity Employer. All employment is decided on the basis of qualifications, merit, and business need. Applicants will receive consideration for employment without regard to race, ethnicity, color, religion, sex gender identity, sexual orientation, national origin, age, disability, protected veteran or disabled status, or other characteristic protected by applicable federal, state, or local law.
Unsolicited resumes from agencies should not be forwarded to Madrigal. Madrigal will not be responsible for any fees arising from the use of resumes through this source. Madrigal will only pay a fee to agencies if a formal agreement between Madrigal and the agency has been established.
Please be aware that we are currently receiving numerous reports of individuals misrepresenting themselves as Madrigal Pharmaceuticals’ Hiring Managers, seeking to engage with job candidates through fraudulent online advertisements or job posting sites. These unauthorized individuals are using Madrigal’s name and logo in an attempt to solicit up-front fees and obtain personal information from interested job candidates. Please know that Madrigal does not conduct interviews via text or in chat rooms; conduct interviews via Skype, RingCentral or solely via telephone; charge candidates an advance fee of any kind (e.g., fees for purchasing equipment); nor does it offer positions of employment without undergoing a thorough recruiting process. Interviews with Madrigal are conducted via the Zoom platform.
Please also note that any correspondence with regard to employment would come from an authorized madrigalpharma.com email address or from an email address from one of our trusted search firm partners. We are aware that incorrect/fraudulent email addresses, with Madrigal misspelled, have been utilized in these most recent fraud attempts. If you receive unsolicited employment offers from people claiming to work for Madrigal we recommend that you: do not respond to their questions; do not open any attachments; and do not click on any hyperlinks.
Similar Jobs
What We Do
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com






